Rating Change
Leerink Partners reiterated its Outperform rating on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) on October 09, 2026.
reiterateNASDAQ:ARCT
Leerink Partners Reiterates Outperform Rating on Arcturus Therapeutics Holdings Inc. (ARCT)
Leerink Partners reiterated its Outperform rating on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) on October 09, 2026.
At publication ·
What changed
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) · reiterate
- Firm
- Leerink Partners
- Rating
- Outperform to Outperform
- Price at event
- $13.74
- Market capitalization
- $233.8M
At a glance
Key takeaways
- Arcturus Therapeutics (ARCT) trades at $13.74 with a market cap of $233.8M and has declined 36.3% over the past 52 weeks.
Market Context
Arcturus Therapeutics Holdings Inc. operates in the Healthcare sector. The stock currently trades at $13.74 with a market capitalization of $233.8M. The stock has declined 36.3% over the past 52 weeks.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Arcturus Therapeutics Holdings Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Arcturus Therapeutics Holdings Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 09, 2026 | Leerink Partners | Outperform | N/A |
| Sep 24, 2026 | BTIG | Buy | N/A |
| Sep 24, 2026 | Citigroup | Buy | N/A |
| Jul 02, 2026 | Freedom Broker | Buy | N/A |
| Mar 18, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ARCT Stock Page
Frequently Asked Questions
What does the Outperform rating mean for ARCT?
A rating of Outperform from Leerink Partners reflects the analyst's outlook on Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ARCT forecast page.